哌柏西利联合内分泌治疗在老年HR+/HER2-晚期乳腺癌中的汇总分析
该汇总分析纳入三项随机研究(PALOMA-1、PALOMA-2、PALOMA-3),评估哌柏西利联合内分泌治疗在≥65岁HR+/HER2-晚期乳腺癌患者中的疗效与安全性。结果显示,与单用内分泌治疗相比,65-74岁及≥75岁患者无进展生存期显著改善,生活质量得以维持,≥III级骨髓抑制在各年龄组间相似,未发现新的安全性问题。
要点
- 哌柏西利联合来曲唑在65-74岁及≥75岁患者中均显著改善无进展生存期。
- 哌柏西利联合氟维司群在65-74岁患者中显著改善无进展生存期,≥75岁患者例数少。
- 老年患者≥III级骨髓抑制发生率与各年龄组相似,发热性中性粒细胞减少不常见。
核心结论
- 哌柏西利联合内分泌治疗是老年HR+/HER2-晚期乳腺癌有效且耐受良好的治疗选择。
研究设计与样本
- 汇总三项随机研究(NCT00721409、NCT01740427、NCT01942135)中HR+/HER2-晚期乳腺癌女性患者数据。
- PALOMA-1为开放标签,PALOMA-2为双盲安慰剂对照,初治患者接受哌柏西利联合来曲唑或单用来曲唑。
- PALOMA-3为双盲安慰剂对照,内分泌耐药患者接受哌柏西利联合氟维司群或单用氟维司群。
- 哌柏西利联合来曲唑组528例中218例(41.3%)≥65岁,哌柏西利联合氟维司群组347例中86例(24.8%)≥65岁。
主要发现
- 65-74岁患者哌柏西利联合来曲唑较单用内分泌治疗显著改善无进展生存期(HR 0.66;95%CI 0.45-0.97;P=0.016)。
- ≥75岁患者哌柏西利联合来曲唑较单用内分泌治疗显著改善无进展生存期(HR 0.31;95%CI 0.16-0.61;P<0.001)。
- 65-74岁患者哌柏西利联合氟维司群较单用内分泌治疗显著改善无进展生存期(HR 0.27;95%CI 0.16-0.48;P<0.001)。
- ≥75岁接受哌柏西利联合氟维司群患者例数少(HR 0.59;95%CI 0.19-1.8;P=0.18)。
- 患者报告的功能与生活质量得以维持,各年龄组间哌柏西利暴露无临床相关差异。
关键数值与推荐
- 65-74岁哌柏西利联合来曲唑组无进展生存期HR 0.66(95%CI 0.45-0.97;P=0.016)。
- ≥75岁哌柏西利联合来曲唑组无进展生存期HR 0.31(95%CI 0.16-0.61;P<0.001)。
- 65-74岁哌柏西利联合氟维司群组无进展生存期HR 0.27(95%CI 0.16-0.48;P<0.001)。
- ≥75岁哌柏西利联合氟维司群组无进展生存期HR 0.59(95%CI 0.19-1.8;P=0.18)。
- 发热性中性粒细胞减少发生率≤2.4%,≥III级骨髓抑制发生率在各年龄组间相似。
临床怎么用
- 对65岁及以上HR+/HER2-晚期乳腺癌患者,可考虑哌柏西利联合来曲唑或氟维司群治疗。
- ≥75岁患者使用哌柏西利联合氟维司群的数据有限,决策时需结合个体情况。
- 治疗期间应关注骨髓抑制,但≥III级骨髓抑制在各年龄组间相似,发热性中性粒细胞减少不常见。
局限性
- 为汇总分析而非预设的老年亚组随机对照研究。
- ≥75岁接受哌柏西利联合氟维司群的患者例数少,结果解释需谨慎。
- PALOMA-1为开放标签研究,可能存在偏倚。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
AIM: Because incidence of breast cancer and comorbidities increase with age, it is important to determine treatment benefit in elderly patients. We evaluated outcomes with palbociclib plus endocrine therapy in patients aged ≥65 years. METHODS: Data were pooled from three randomised studies (NCT00721409, NCT01740427 and NCT01942135) of women with HR+/HER2- advanced breast cancer (ABC). In PALOMA-1 (open-label) and PALOMA-2 (double-blind, placebo-controlled), treatment-naïve patients received palbociclib plus letrozole or letrozole alone. In PALOMA-3 (double-blind, placebo-controlled), patients with endocrine-resistant disease received palbociclib plus fulvestrant or fulvestrant alone. RESULTS: Among 528 patients treated with palbociclib plus letrozole and 347 treated with palbociclib plus fulvestrant, 218 (41.3%) and 86 (24.8%), respectively, were aged ≥65 years. Versus endocrine therapy alone, median progression-free survival was significantly improved in patients aged 65-74 years (hazard ratio [HR], 0.66; 95% confidence interval [CI], 0.45-0.97; P = 0.016) and ≥75 years (HR, 0.31; 95% CI, 0.16-0.61; P<0.001) receiving palbociclib plus letrozole and in patients aged 65-74 years (HR, 0.27; 95% CI, 0.16-0.48; P<0.001) receiving palbociclib plus fulvestrant; few patients aged ≥75 years received palbociclib plus fulvestrant (HR, 0.59; 95% CI, 0.19-1.8; P = 0.18). Patient-reported functioning and quality of life was maintained. No clinically relevant differences in palbociclib exposure were observed between age groups. Although myelosuppression was more common among patients aged ≥75 years, incidence of grade ≥III myelosuppression was similar across age groups, and febrile neutropenia was uncommon (≤2.4%); no new safety concerns were identified in older patients. CONCLUSIONS: Palbociclib plus endocrine therapy is an effective, well-tolerated treatment for older patients with ABC.
引用
- Rugo HS, Turner NC, Finn RS, et al. Palbociclib plus endocrine therapy in older women with HR+/HER2- advanced breast cancer: a pooled analysis of randomised PALOMA clinical studies. Eur J Cancer. 2018. PMID: 30053671. doi:10.1016/j.ejca.2018.05.017
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。